Consensus recommendations on communication, language and speech in Phelan-McDermid syndrome

被引:6
|
作者
Burdeus-Olavarrieta, Monica [1 ,2 ]
Nevado, Julian [3 ,4 ,5 ]
van Weering-Scholten, Sabrina [6 ]
Parker, Susanne [7 ]
Swillen, Ann [9 ,10 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Inst Psychiat & Mental Hlth, Dept Child & Adolescent Psychiat, IiSGM, Madrid, Spain
[2] Univ Autonoma, Sch Psychol, Madrid, Spain
[3] Hosp Univ La Paz, Inst Genet Med & Mol INGEMM IdiPAZ, Madrid, Spain
[4] ISCIII, Ctr Invest Biomed Red Enfermedades Raras, CIBERER, Madrid, Spain
[5] Hosp La Paz, ITHACA European Reference Network, Madrid, Spain
[6] Univ Med Ctr Groningen, Beatrixoord Childrens Rehabil, Groningen, Netherlands
[7] Univ Klinikum Ulm, Phelan McDermid Gesell eV Geschaftsstelle, Sekretariat Neurol, Oberer Eselsberg 45, D-89081 Ulm, Germany
[8] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands
[9] Univ Hosp Leuven, Ctr Human Genet, Leuven, Belgium
[10] Katholieke Univ Leuven, Dept Human Genet, Herestr 49, B-3000 Leuven, Belgium
基金
欧盟地平线“2020”;
关键词
Phelan-McDermid syndrome; 22q13 deletion syndrome; SHANK3; Communication; Language; Speech; MINIMALLY VERBAL CHILDREN; 22Q13.3 DELETION SYNDROME; AUTISM;
D O I
10.1016/j.ejmg.2023.104745
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Phelan-McDermid syndrome is a genetic condition primarily caused by a deletion on the 22q13.3 region or a likely pathogenic/pathogenic variant of SHANK3. The main features comprise global developmental delay, marked impairment or absence of speech, and other clinical characteristics to a variable degree, such as hypo-tonia or psychiatric comorbidities. A set of clinical guidelines for health professionals covering relevant aspects of clinical management have been written by the European PMS Consortium, and consensus has been reached regarding final recommendations. In this work, attention is given to communication, language and speech im-pairments in PMS, and the findings from available literature are presented. Findings from the literature review reveal marked speech impairment in up to 88% of deletions and 70% of SHANK3 variants. Absence of speech is frequent and affects 50%-80% of the individuals with PMS. Communicative skills in the expressive domain other than spoken language remain understudied, but some studies offer data on non-verbal language or the use of alternative/augmentative communication support. Loss of language and other developmental skills is reported in around 40% of individuals, with variable course. Deletion size and possibly other clinical variables (e.g., conductive hearing problems, neurological issues, intellectual disability, etc.) are related to communicative and linguistic abilities. Recommendations include regular medical check-ups of hearing and the assessment of other factors influencing communication, thorough evaluation of preverbal and verbal communicative skills, early intervention, and support via alternative/augmentative communication systems.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] EXPERIMENTAL THERAPEUTICS IN PHELAN-MCDERMID SYNDROME
    Kolevzon, Alexander
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2024, 63 (10): : S79 - S79
  • [22] Consensus recommendations on counselling in Phelan-McDermid syndrome, with special attention to recurrence risk and to ring chromosome 22
    Koza, Sylvia A.
    Tabet, Anne C.
    Bonaglia, Maria C.
    Andres, Stephanie
    Anderlid, Britt -Marie.
    Aten, Emmelien
    Stiefsohn, Dominique
    Evans, D. Gareth
    van Ravenswaaij-Arts, Conny M. A.
    Kant, Sarina G.
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2023, 66 (07)
  • [23] Prevalence of the Phelan-McDermid Syndrome in Spain
    Gomez Taylor, Barbara
    Moreno Sancho, Mari Luz
    Drehmer Rieger, Eraci
    Carrera Julia, Sandra
    Nevado, Julian
    Sempere Ferre, Francisca
    REVISTA ESPANOLA DE SALUD PUBLICA, 2020, 94
  • [24] Increased Radiosensitivity in Patients with Phelan-McDermid Syndrome
    Jesse, Sarah
    Kuhlmann, Lukas
    Hildebrand, Laura
    Schmaus, M. C.
    Timmermann, Beate
    Andres, Stephanie
    Fietkau, Rainer
    Distel, Luitpold
    STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 : S82 - S82
  • [25] The impact of Phelan-McDermid syndrome on the child and family
    Phelan, Katy
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2023, 65 (07): : 862 - 863
  • [26] Phelan-mcdermid syndrome and atypical bipolar disorder
    Verhoeven, W.
    Egger, J.
    De Leeuw, N.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [27] Opportunities for ABA intervention in Phelan-McDermid syndrome
    Schroeder, Kate A.
    Witts, Benjamin N.
    Traub, Michele R.
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES, 2022, 68 (06) : 984 - 989
  • [28] Characterisation of the clinical phenotype in Phelan-McDermid syndrome
    Mónica Burdeus-Olavarrieta
    Antonia San José-Cáceres
    Alicia García-Alcón
    Javier González-Peñas
    Patricia Hernández-Jusdado
    Mara Parellada-Redondo
    Journal of Neurodevelopmental Disorders, 2021, 13
  • [29] The Relationship Between Neuropsychiatric Symptoms and Language Ability in Phelan-McDermid Syndrome
    Friedman, Kate
    Levy, Tess
    Srivastava, Siddharth
    Kohlenberg, Teresa M.
    Kolevzon, Alexander
    BIOLOGICAL PSYCHIATRY, 2024, 95 (10) : S225 - S226
  • [30] Gait Abnormalities in Children with Phelan-McDermid Syndrome
    Frank, Yitzchak
    Levy, Tess
    Lozano, Reymundo
    Friedman, Kate
    Underwood, Slayton
    Kostic, Ana
    Walker, Hannah
    Kolevzon, Alexander
    JOURNAL OF CHILD NEUROLOGY, 2023, 38 (13-14) : 665 - 671